Inhaled frusemide does not affect lung mucociliary clearance in healthy and asthmatic subjects

Eur Respir J. 1994 Aug;7(8):1497-500. doi: 10.1183/09031936.94.07081497.

Abstract

Inhaled frusemide has been shown to protect against the bronchoconstrictor effect of several inhaled agents in asthmatic subjects by mechanism(s) that are unclear. Since loop diuretics can modulate Cl- transport in the airway epithelium, frusemide may alter the quality and/or the quantity of the periciliary layer, which in turn may affect lung mucociliary transport. We investigated the effect of a single inhalation of nebulized frusemide (40 mg) on lung mucociliary clearance in four healthy subjects and in seven stable, mild asthmatics using an objective radioaerosol technique. Frusemide or placebo was inhaled in a double-blind, randomized, cross-over manner half an hour after the inhalation of 5 microns polystyrene particles labelled with 99mTc, used for assessing mucociliary clearance. The pulmonary function and initial radioaerosol distribution were similar between frusemide and placebo runs within each of the two study groups. The areas under the tracheobronchial retention curves over the 6 h observation period were similar between frusemide and placebo runs for both groups. Our findings show inhaled frusemide, at a dose known to inhibit bronchoconstrictor responses, does not affect lung mucociliary clearance.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Administration, Inhalation
  • Adult
  • Aerosols
  • Asthma / physiopathology*
  • Cross-Over Studies
  • Double-Blind Method
  • Female
  • Furosemide / administration & dosage*
  • Furosemide / pharmacology
  • Humans
  • Male
  • Mucociliary Clearance / drug effects*
  • Technetium

Substances

  • Aerosols
  • Technetium
  • Furosemide